Phase 3 N=228 A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Allergic Conjunctivitis
Primary: Ocular Itching — 1.609; 1.886; 2.219; 1.750 units on a scale — p=< 0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=361 A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
Papulopustular Rosacea
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants
Phase 3 N=797 A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Alzheimer's Disease
Primary: Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase) — 1.19; 1.41; 1.47 Scores on a…
Phase 3 N=508 Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
Dry Eye Syndrome · Keratoconjunctivitis Sicca
Primary: Number of Subjects With a ≥10 mm Increase From Baseline in Schirmer Tear Test (STT) — 12; 10; 13; 6 participants — p=0.1352
Phase 3 N=27 A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
Pyruvate Kinase Deficiency · Anemia, Hemolytic
Primary: Percentage of Participants Achieving a Reduction in Transfusion Burden in Part 2 — 37 percentage of participants — p=0.0002
Phase 3 N=544 Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
Schizophrenia
Primary: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set — 53; 13; 23 Participants — p=<0.0001
Phase 3 N=25 A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Primary Hyperoxaluria
Primary: Change From Baseline in Plasma Oxalate Concentration After 52 Weeks of Treatment — 14.8; 14.4; -0.71; 2.35 micromole/liter
Phase 3 N=150 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Asthma
Primary: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control — 40; 35; 5; 4 Participants — p=0.434
Phase 3 N=223 Asthma Action at Erie Trial
Asthma · Children
Primary: Asthma Control Test/Childhood Asthma Control Test at 12-months — 21.23; 20.58 score on a scale
Phase 3 N=407 Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™ — 9.4; 5.9; 10.3; 6.4 Percentage of Participants
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 3 N=838 A Study of Paliperidone Palmitate 6-Month Formulation
Schizophrenia
Primary: Time to Relapse During the Double-Blind (DB) Phase — NA; NA Days
Phase 3 N=342 Selinexor in Advanced Liposarcoma
Dedifferentiated Liposarcoma
Primary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 2.83; 2.07 Months — p=0.0114
Phase 3 N=166 Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score…
Phase 3 N=26 Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Obesity
Primary: Pain Scores (Numerical Rating Scale 0-10) Using the Faces Pain Scale-Revised — 5; 3.4 Units on a scale